The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of
nicotinic acetylcholine receptor implicated in long-term memory, consisting entirely of
α7subunits.[1] As with other nicotinic acetylcholine receptors, functional α7 receptors are
pentameric [i.e., (α7)5stoichiometry].
Further, recent work has implicated this receptor as being important for generation of adult mammal neurons in the retina.[2] Functional α7 receptors are present in the
submucous plexus neurons of the guinea-pig
ileum.[3]
NS-1738: marginal effects on α7 desensitization kinetics; modestly brain-penetrant[31]
AVL-3288: unlike the above PAMs, AVL-3288 does not affect α7 desensitization kinetics, and is readily brain penetrant. Improves cognitive behavior in animal models[32] In clinical development for cognitive deficits in schizophrenia.
It is found that
anandamide and ethanol cause an additive inhibition on the function of α7-receptor by interacting with distinct regions of the receptor. Although
ethanol inhibition of the α7-receptor is likely to involve the
N-terminal region of the receptor, the site of action for anandamide is located in the
transmembrane and
carboxyl-terminal domains of the receptors.[38]
^Glushakov AV, Voytenko LP, Skok MV, Skok V (January 2004). "Distribution of neuronal nicotinic acetylcholine receptors containing different alpha-subunits in the submucosal plexus of the guinea-pig". Autonomic Neuroscience. 110 (1): 19–26.
doi:
10.1016/j.autneu.2003.08.012.
PMID14766321.
S2CID25872540.
^Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, et al. (March 2012). "MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway". Angiogenesis. 15 (1): 99–114.
doi:
10.1007/s10456-011-9246-9.
PMID22198237.
S2CID17889977.
^Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (April 2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 16–27.
CiteSeerX10.1.1.420.2457.
doi:
10.1124/jpet.103.061655.
PMID14722323.
S2CID7730290.
^Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC (January 2014). "Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia". Journal of Psychiatric Practice. 20 (1): 12–24.
doi:
10.1097/01.pra.0000442935.15833.c5.
PMID24419307.
S2CID19669958.
^
abSadigh-Eteghad S, Talebi M, Mahmoudi J, Babri S, Shanehbandi D (July 2015). "Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice". Neuroscience. 298: 81–93.
doi:
10.1016/j.neuroscience.2015.04.017.
PMID25881725.
S2CID22477612.
^Bali ZK, Inkeller J, Csurgyók R, Bruszt N, Horváth H, Hernádi I (February 2015). "Differential effects of α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models". Behavioural Brain Research. 278: 404–10.
doi:
10.1016/j.bbr.2014.10.030.
PMID25447295.
S2CID10791918.
^Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, et al. (June 2008). "Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity". Bioorganic & Medicinal Chemistry Letters. 18 (12): 3611–5.
doi:
10.1016/j.bmcl.2008.04.070.
PMID18490160.
^Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, et al. (December 2006). "Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists". Bioorganic & Medicinal Chemistry. 14 (24): 8219–48.
doi:
10.1016/j.bmc.2006.09.019.
PMID17011782.
^Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. (February 2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorganic & Medicinal Chemistry Letters. 11 (3): 319–21.
doi:
10.1016/S0960-894X(00)00670-3.
PMID11212100.
^Dallanoce C, Matera C, De Amici M, Rizzi L, Pucci L, Gotti C, Clementi F, De Micheli C (July 2012). "The enantiomers of epiboxidine and of two related analogs: synthesis and estimation of their binding affinity at α4β2 and α7 neuronal nicotinic acetylcholine receptors". Chirality. 24 (7): 543–51.
doi:
10.1002/chir.22052.
PMID22566097.
^Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, et al. (October 2007). "An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 294–307.
doi:
10.1124/jpet.107.120436.
PMID17625074.
S2CID35392171.
^Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, et al. (May 2009). "Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor". Journal of Medicinal Chemistry. 52 (10): 3377–84.
doi:
10.1021/jm9003818.
PMID19419141.
^Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, et al. (July 2009). "In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile". The Journal of Pharmacology and Experimental Therapeutics. 330 (1): 257–67.
doi:
10.1124/jpet.109.151886.
PMID19389923.
S2CID5470552.
^Nishizaki T, Nomura T, Matuoka T, Kondoh T, Enikolopov G, Enikolopo G, Sumikawa K, Watabe S, Shiotani T, Yoshii M (August 2000). "The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors". Brain Research. Molecular Brain Research. 80 (1): 53–62.
doi:
10.1016/S0169-328X(00)00117-0.
PMID11039729.
^Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T (April 2001). "Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons". Molecular Pharmacology. 59 (4): 674–83.
doi:
10.1124/mol.59.4.674.
PMID11259610.
S2CID27825145.
^Nishizaki T, Matsuoka T, Nomura T, Kondoh T, Watabe S, Shiotani T, Yoshii M (2000). "Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission". Alzheimer Disease and Associated Disorders. 14 (Suppl 1): S82–94.
doi:
10.1097/00002093-200000001-00013.
PMID10850735.
S2CID25914087.
^Oz M, Jackson SN, Woods AS, Morales M, Zhang L (June 2005). "Additive effects of endogenous cannabinoid anandamide and ethanol on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1272–80.
doi:
10.1124/jpet.104.081315.
PMID15687372.
S2CID23201726.
^Whiteaker P, Christensen S, Yoshikami D, Dowell C, Watkins M, Gulyas J, et al. (June 2007). "Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist". Biochemistry. 46 (22): 6628–38.
doi:
10.1021/bi7004202.
PMID17497892.
^Sharma, Charu; Al Kaabi, Juma M.; Nurulain, Syed M.; Goyal, Sameer N.; Kamal, Mohammad Amjad; Ojha, Shreesh (2016). "Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise". Current Pharmaceutical Design. 22 (21): 3237–3264.
doi:
10.2174/1381612822666160311115226.
ISSN1873-4286.
PMID26965491.
^Tsuneki H, You Y, Toyooka N, Kagawa S, Kobayashi S, Sasaoka T, et al. (October 2004). "Alkaloids indolizidine 235B', quinolizidine 1-epi-207I, and the tricyclic 205B are potent and selective noncompetitive inhibitors of nicotinic acetylcholine receptors". Molecular Pharmacology. 66 (4): 1061–9.
doi:
10.1124/mol.104.000729.
PMID15258256.
S2CID17490742.
The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of
nicotinic acetylcholine receptor implicated in long-term memory, consisting entirely of
α7subunits.[1] As with other nicotinic acetylcholine receptors, functional α7 receptors are
pentameric [i.e., (α7)5stoichiometry].
Further, recent work has implicated this receptor as being important for generation of adult mammal neurons in the retina.[2] Functional α7 receptors are present in the
submucous plexus neurons of the guinea-pig
ileum.[3]
NS-1738: marginal effects on α7 desensitization kinetics; modestly brain-penetrant[31]
AVL-3288: unlike the above PAMs, AVL-3288 does not affect α7 desensitization kinetics, and is readily brain penetrant. Improves cognitive behavior in animal models[32] In clinical development for cognitive deficits in schizophrenia.
It is found that
anandamide and ethanol cause an additive inhibition on the function of α7-receptor by interacting with distinct regions of the receptor. Although
ethanol inhibition of the α7-receptor is likely to involve the
N-terminal region of the receptor, the site of action for anandamide is located in the
transmembrane and
carboxyl-terminal domains of the receptors.[38]
^Glushakov AV, Voytenko LP, Skok MV, Skok V (January 2004). "Distribution of neuronal nicotinic acetylcholine receptors containing different alpha-subunits in the submucosal plexus of the guinea-pig". Autonomic Neuroscience. 110 (1): 19–26.
doi:
10.1016/j.autneu.2003.08.012.
PMID14766321.
S2CID25872540.
^Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, et al. (March 2012). "MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway". Angiogenesis. 15 (1): 99–114.
doi:
10.1007/s10456-011-9246-9.
PMID22198237.
S2CID17889977.
^Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (April 2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 16–27.
CiteSeerX10.1.1.420.2457.
doi:
10.1124/jpet.103.061655.
PMID14722323.
S2CID7730290.
^Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC (January 2014). "Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia". Journal of Psychiatric Practice. 20 (1): 12–24.
doi:
10.1097/01.pra.0000442935.15833.c5.
PMID24419307.
S2CID19669958.
^
abSadigh-Eteghad S, Talebi M, Mahmoudi J, Babri S, Shanehbandi D (July 2015). "Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice". Neuroscience. 298: 81–93.
doi:
10.1016/j.neuroscience.2015.04.017.
PMID25881725.
S2CID22477612.
^Bali ZK, Inkeller J, Csurgyók R, Bruszt N, Horváth H, Hernádi I (February 2015). "Differential effects of α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models". Behavioural Brain Research. 278: 404–10.
doi:
10.1016/j.bbr.2014.10.030.
PMID25447295.
S2CID10791918.
^Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, et al. (June 2008). "Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity". Bioorganic & Medicinal Chemistry Letters. 18 (12): 3611–5.
doi:
10.1016/j.bmcl.2008.04.070.
PMID18490160.
^Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, et al. (December 2006). "Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists". Bioorganic & Medicinal Chemistry. 14 (24): 8219–48.
doi:
10.1016/j.bmc.2006.09.019.
PMID17011782.
^Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. (February 2001). "The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist". Bioorganic & Medicinal Chemistry Letters. 11 (3): 319–21.
doi:
10.1016/S0960-894X(00)00670-3.
PMID11212100.
^Dallanoce C, Matera C, De Amici M, Rizzi L, Pucci L, Gotti C, Clementi F, De Micheli C (July 2012). "The enantiomers of epiboxidine and of two related analogs: synthesis and estimation of their binding affinity at α4β2 and α7 neuronal nicotinic acetylcholine receptors". Chirality. 24 (7): 543–51.
doi:
10.1002/chir.22052.
PMID22566097.
^Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, et al. (October 2007). "An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 294–307.
doi:
10.1124/jpet.107.120436.
PMID17625074.
S2CID35392171.
^Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, et al. (May 2009). "Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor". Journal of Medicinal Chemistry. 52 (10): 3377–84.
doi:
10.1021/jm9003818.
PMID19419141.
^Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, et al. (July 2009). "In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile". The Journal of Pharmacology and Experimental Therapeutics. 330 (1): 257–67.
doi:
10.1124/jpet.109.151886.
PMID19389923.
S2CID5470552.
^Nishizaki T, Nomura T, Matuoka T, Kondoh T, Enikolopov G, Enikolopo G, Sumikawa K, Watabe S, Shiotani T, Yoshii M (August 2000). "The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors". Brain Research. Molecular Brain Research. 80 (1): 53–62.
doi:
10.1016/S0169-328X(00)00117-0.
PMID11039729.
^Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T (April 2001). "Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons". Molecular Pharmacology. 59 (4): 674–83.
doi:
10.1124/mol.59.4.674.
PMID11259610.
S2CID27825145.
^Nishizaki T, Matsuoka T, Nomura T, Kondoh T, Watabe S, Shiotani T, Yoshii M (2000). "Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission". Alzheimer Disease and Associated Disorders. 14 (Suppl 1): S82–94.
doi:
10.1097/00002093-200000001-00013.
PMID10850735.
S2CID25914087.
^Oz M, Jackson SN, Woods AS, Morales M, Zhang L (June 2005). "Additive effects of endogenous cannabinoid anandamide and ethanol on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1272–80.
doi:
10.1124/jpet.104.081315.
PMID15687372.
S2CID23201726.
^Whiteaker P, Christensen S, Yoshikami D, Dowell C, Watkins M, Gulyas J, et al. (June 2007). "Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist". Biochemistry. 46 (22): 6628–38.
doi:
10.1021/bi7004202.
PMID17497892.
^Sharma, Charu; Al Kaabi, Juma M.; Nurulain, Syed M.; Goyal, Sameer N.; Kamal, Mohammad Amjad; Ojha, Shreesh (2016). "Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise". Current Pharmaceutical Design. 22 (21): 3237–3264.
doi:
10.2174/1381612822666160311115226.
ISSN1873-4286.
PMID26965491.
^Tsuneki H, You Y, Toyooka N, Kagawa S, Kobayashi S, Sasaoka T, et al. (October 2004). "Alkaloids indolizidine 235B', quinolizidine 1-epi-207I, and the tricyclic 205B are potent and selective noncompetitive inhibitors of nicotinic acetylcholine receptors". Molecular Pharmacology. 66 (4): 1061–9.
doi:
10.1124/mol.104.000729.
PMID15258256.
S2CID17490742.